Clinical data | |
---|---|
Pronunciation | /lænˈsoʊprəzoʊl/ lan-SOH-prə-zohl |
Trade names | Prevacid, others |
Other names | AG 1749 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a695020 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Proton pump inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80% or more |
Protein binding | 97% |
Metabolism | Liver ( CYP3A4- and CYP2C19-mediated) |
Elimination half-life | 1.0–1.5 hours |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.173.220 |
Chemical and physical data | |
Formula | C16H14F3N3O2S |
Molar mass | 369.36 g·mol−1 |
3D model ( JSmol) | |
Chirality | Racemic mixture |
Melting point | 178 °C (352 °F) (decomposes) |
| |
| |
(verify) |
Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. [4] It is a proton pump inhibitor (PPI), used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [5] Its effectiveness is similar to that of other PPIs. [6] It is taken by mouth. [4] Onset is over a few hours and effects last up to a couple of days. [4]
Common side effects include constipation, abdominal pain, and nausea. [4] [3] Serious side effects may include osteoporosis, low blood magnesium, Clostridium difficile infection, and pneumonia. [4] [3] Use in pregnancy and breastfeeding is of unclear safety. [1] It works by blocking H+/K+-ATPase in the parietal cells of the stomach. [4]
Lansoprazole was patented in 1984 and came into medical use in 1992. [7] It is available as a generic medication. [5] In 2021, it was the 216th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [8] [9]
Lansoprazole is used for treatment of: [3]
There is no good evidence that it works better than other PPIs. [6]
Side effects of PPIs in general [11] and lansoprazole in particular [12] may include: [3]
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea. [3]: 22
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI. [16]
Lansoprazole possibly interacts with, among other drugs:
It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole. [18] Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). [19]
Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749. [20] Takeda patented it in 1984 and the drug launched in 1991. [21] In the United States, it was approved for medical use in 1995. [22]
Patent protection of the lansoprazole molecule expired on 10 November 2009, [23] [24] and generic formulations became available under many brand names in many countries. [25] Some formulations may not be available in generic form. [26]
Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. as Prevacid 24HR [27] [28] and as Lansoprazole 24HR. [29] In Australia, it is marketed by Pfizer as Zoton. [30]
In vitro experiments have shown that lansoprazole binds to the pathogenic form of tau protein. [31] As of 2015 [update] laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease. [31]
Clinical data | |
---|---|
Pronunciation | /lænˈsoʊprəzoʊl/ lan-SOH-prə-zohl |
Trade names | Prevacid, others |
Other names | AG 1749 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a695020 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous |
Drug class | Proton pump inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80% or more |
Protein binding | 97% |
Metabolism | Liver ( CYP3A4- and CYP2C19-mediated) |
Elimination half-life | 1.0–1.5 hours |
Excretion | Kidney and fecal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.173.220 |
Chemical and physical data | |
Formula | C16H14F3N3O2S |
Molar mass | 369.36 g·mol−1 |
3D model ( JSmol) | |
Chirality | Racemic mixture |
Melting point | 178 °C (352 °F) (decomposes) |
| |
| |
(verify) |
Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid. [4] It is a proton pump inhibitor (PPI), used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome. [5] Its effectiveness is similar to that of other PPIs. [6] It is taken by mouth. [4] Onset is over a few hours and effects last up to a couple of days. [4]
Common side effects include constipation, abdominal pain, and nausea. [4] [3] Serious side effects may include osteoporosis, low blood magnesium, Clostridium difficile infection, and pneumonia. [4] [3] Use in pregnancy and breastfeeding is of unclear safety. [1] It works by blocking H+/K+-ATPase in the parietal cells of the stomach. [4]
Lansoprazole was patented in 1984 and came into medical use in 1992. [7] It is available as a generic medication. [5] In 2021, it was the 216th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [8] [9]
Lansoprazole is used for treatment of: [3]
There is no good evidence that it works better than other PPIs. [6]
Side effects of PPIs in general [11] and lansoprazole in particular [12] may include: [3]
PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea. [3]: 22
Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI. [16]
Lansoprazole possibly interacts with, among other drugs:
It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole. [18] Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression). [19]
Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749. [20] Takeda patented it in 1984 and the drug launched in 1991. [21] In the United States, it was approved for medical use in 1995. [22]
Patent protection of the lansoprazole molecule expired on 10 November 2009, [23] [24] and generic formulations became available under many brand names in many countries. [25] Some formulations may not be available in generic form. [26]
Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. as Prevacid 24HR [27] [28] and as Lansoprazole 24HR. [29] In Australia, it is marketed by Pfizer as Zoton. [30]
In vitro experiments have shown that lansoprazole binds to the pathogenic form of tau protein. [31] As of 2015 [update] laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease. [31]